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Abstract
I In nt tr ro od du uc ct ti io on n: :   Nucleotide 1311 polymorphism at exon 11 of the glucose-6-
phosphate dehydrogenase (G6PD) gene is fairly common in various populations
worldwide, especially among Mediterranean populations. In this study, 1311 poly  -
morphism in G6PD-deficient cases was identified by microarray technique. 
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   Four hundred and fifty clinically healthy subjects were
screened and 32 cases were found to have G6PD deficiency (7.11%). Our analysis
of genomic DNA samples from 32 G6PD-deficient individuals revealed that the
number and percentage of subjects who had a C-to-T alteration at nucleotide
1311 were 21 and 4.7% respectively. Given that the frequency of 1311 poly  -
morphism has been reported in previous studies to be fairly high among 
G6PD-deficient people with the Mediterranean mutation, our data seem to be
inconsistent with what we would expect for this particular region. 
R Re es su ul lt ts s: :   The highly diverse ethnic background of the Adana population which
probably results from the high level of immigration into this part of Turkey may
be  one  of  the  most  sensible  explanations  for  this  unexpected  finding.
Nevertheless, it seems that our results need to be confirmed in larger studies.
C Co on nc cl lu us si io on ns s: :   The polymorphism studies in the G6PD gene may help us to
illuminate the genetic basis of the G6PD deficiency in different regions and in
various  ethnic  groups,  and  also  to  discover  the  influence  of  a specific
polymorphism on the clinical course of the deficiency. 
K Ke ey y   w wo or rd ds s: :   1311 polymorphism, G6PD deficiency, microarray technique.
Introduction
Glucose-6-phosphate dehydrogenase (G6PD) enzyme is encoded by
the G6PD gene, which is localized on the X chromosome (Xq28), spans
over 18 kb, and is composed of 13 exons and 12 introns [1]. The G6PD 
is expressed in all cells and is responsible for the first reaction of the
pentose phosphate pathway in which glucose-6-phosphate is oxidized to 
6-phosphogluconolactone with concomitant production of NADPH [2].
Approximately 150 mutations in the G6PD gene have been documented
so far, most of them being single-base substitutions leading to amino acid
replacements [3]. The G6PD deficiency, inherited as an X-linked disorder,
is the most common enzymopathy that produces disease affecting nearly
400 million people worldwide [4]. With more than 300 reported variants,
the disease is highly polymorphic. Furthermore, it has been shown to
provide protection against malaria, which probably explains its high
frequency in some geographical regions [5]. Indeed, G6PD deficiency occurs
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with an increased rate throughout Africa, Asia, the
Mediterranean, and the Middle East [6]. In Turkey,
the frequency of G6PD deficiency varies greatly
between 0.5% and 20% with the genetic and ethnic
background of the population studied [7]. However,
the overall incidence was stated to be 0.5% and
8.2% in Turkey and in Adana, the biggest city of the
Cukurova Plain located at the southeast coast of
the Mediterranean Sea, respectively [7, 8].
Although most patients are asymptomatic, G6PD
deficiency can cause a spectrum of diseases including
neonatal hyperbilirubinaemia, acute and chronic
haemolysis, and so on. The disease is typically more
severe in subjects who are homozygous for the
deficiency, and these patients generally present with
or  report  a history  of  neonatal  jaundice,  often
requiring exchange transfusion. A history of infection,
food or drug-induced haemolysis is also common [9,
10]. The G6PD-deficient variants are grouped into
different classes corresponding with disease severity
that varies significantly among racial groups, and
severe deficient variants primarily occur in the
Mediterranean population [11, 12]. Previous reports
indicated that Mediterranean mutation is the main
variant  throughout  Turkey  [13],  and  the  silent
polymorphism at nucleotide position 1311 (C-T) in
exon 11, which would not produce any substitution
at the amino acid level, has been shown with a high
frequency in various populations, particularly in
subjects with the Mediterranean mutation [14].
The G6PD enzyme activity is usually measured via
quantitative spectrophotometric enzymatic assay
which is based on the detection of the rate of NADPH
generation from NADP . A number of other tests are
also available but the fluorescent spot test has been
considered to be one of the simplest, most reliable
and the most sensitive screening tests for G6PD [15].
Furthermore, DNA microarray assays, an alternative
method for rapidly genotyping large numbers of
mutations, have also been utilized to detect G6PD-
deficient individuals in specific populations [16]. In
the present study, we report our results of 1311 (C-T)
polymorphisms in 32 G6PD-deficient individuals in
Adana, Turkey using the microarray technique. 
Material and methods
Blood samples were obtained from 450 clinically
healthy volunteers living in the Cukurova region of
Turkey and collected into EDTA-containing tubes.
To  diagnose  G6PD  deficiency,  the  erythrocyte
enzyme activity was measured using Beutler’s test
[17], and 32 out of all cases (7.11%) were shown to
have G6PD deficiency with an enzyme activity in
the range 0-4.9 U/gHb.
We created a microarray-based assay for the
detection of 1311 polymorphism in Adana, utilizing
electronic microarray technology on the NanoChip™
Molecular Biology Workstation (Nanogen, Inc., San
Diego, CA, USA). The fully automated system allows
the  active  deposition  and  concentration  of
negatively  charged  biotinylated  molecules  on
selected test sites using a proprietary semicon  -
ductor microchip. The DNA at each pad is then
hybridized with specific Cy5- and Cy3-labelled
oligonucleotide reporters, complementary to wild-
type or mutant sequences. Through well-developed,
digital image-processing operations, the array is
imaged;  fluorescence  signals  are  detected,
displayed, and finally evaluated. After thermal
stringency was applied, the remaining reporter
signals were quantified to determine the genotype
of the hybridized genomic DNA sample.
In the first step of the microarray-based assay,
DNAs were isolated from white blood cells as
described by Poncz et al. to perform molecular
diagnostic tests [18]. The PCR mixture contained
75 mM Tris-HCl (pH 8.8), 20 mM (NH4)2SO4, 1.5 mM
MgCl2, 0.2 mM of each dNTP, 10 pmol primer mix,
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0.75 units of Taq polymerase and 100 ng of genomic
DNA in a total volume of 25 µl. Thermocycling was
performed  on  a Perkin  Elmer  9600  system
(Norwalk, Connecticut, USA) using the following
conditions: Subsequent to denaturation at 95°C for
5 min, 35 cycles consisted of 1 min at 95°C, 1 min
at 60°C, 1 min at 72°C, and a final extension at 72°C
for 10 min were performed. 
After purification from excess unincorporated
primers and desalting, the PCR products were
mixed  with  histidine,  and  then  electronically
addressed. Afterwards, the amplified products were
denatured using 0.1 M sodium hydroxide for 3 min
and  then  the  cartridge  was  incubated  with
stabilizers in a high salt buffer for another 3 min.
Following  hybridization  of  probes,  a thermal
stringency step specific for 1311 polymorphism was
carried out in the Reader and hybridization was
detected through fluorescence using automated
scanning  and  dedicated  software.  Restriction
fragment length polymorphism (RFLP) was used to
confirm the C1311T mutation.
C Ca as se e   n no o. .   a an nd d   s se ex x R Re ed d G Gr re ee en n R Ra at te e   ( (R R/ /G G) ) P Pr ro ob b    G Ge en no ot ty yp pe e
1. Gd 1311 Control 237 3.33 21.72 Red/red Control
2. M 39 4.43 8.79 : 1 Red/red Hemizygous
3. F 42 280.5 1 : 6.68 G Gr re ee en n/ /g gr re ee en n N No or rm ma al l
4. M 99 17.74 5.58 : 1 Red/red Hemizygous
5. F 2 1331.54 1 : 665.77 G Gr re ee en n/ /g gr re ee en n N No or rm ma al l
6. F 0 1579.89 Endless G Gr re ee en n/ /g gr re ee en n N No or rm ma al l
7. M 272 48.31 5.63 : 1 Red/red Hemizygous
8. M 14 900.26 1 : 64.3 G Gr re ee en n/ /g gr re ee en n N No or rm ma al l
9. M0 2197.43 Endless  G Gr re ee en n/ /g gr re ee en n N No or rm ma al l
10. M0 282.72 Endless  G Gr re ee en n/ /g gr re ee en n N No or rm ma al l
11. F 0 1637.54 Endless  G Gr re ee en n/ /g gr re ee en n N No or rm ma al l
12. F 51 51 1 : 1 Red/green Heterozygous
13. F 259 11.09 23.36 : 1 Red/red Homozygous
14. F 418 14.41 29 : 1 Red/red Homozygous
15. F 15 2734.04 1 : 182.27 G Gr re ee en n/ /g gr re ee en n N No or rm ma al l
16. M 436 85.37 5.11 : 1 Red/red Hemizygous
17. M 311 16.63 18.7 : 1 Red/red Hemizygous
18. M 261 9.98 26.16 : 1 Red/red Hemizygous
19. F 317 14.41 23.83 : 1 Red/red Homozygous
20. M 282 9.98 28.26 : 1 Red/red Hemizygous
21. F 207 14.41 14.36 : 1 Red/red Homozygous
22. M 174 9.98 17.44 : 1 Red/red Hemizygous
23. M 197 6.65 29.61 : 1 Red/red Hemizygous
24. M7 1544.41 1 : 220.63  G Gr re ee en n/ /g gr re ee en n N No or rm ma al l
25. M 296 35.48 8.34 : 1 Red/red Hemizygous
26. M 235 9.98 23.55 : 1 Red/red Hemizygous
27. F 304 6.65 45.7 : 1 Red/red Homozygous
28. M 162 6.65 24.35 : 1 Red/red Hemizygous
29. M 188 6.65 28.26 : 1 Red/red Hemizygous
30. M 232 7.76 29.89 : 1 Red/red Hemizygous
31. M 246 6.65 3698 : 1 Red/red Hemizygous
32. F 155 838.55 1 : 5.41 G Gr re ee en n/ /g gr re ee en n N No or rm ma al l
33. M 15 88.7 1 : 5.91 G Gr re ee en n/ /g gr re ee en n N No or rm ma al l
T Ta ab bl le e   I I. . The fluorescence signal rates from microarray analysis and the genotype of 1311 polymorphism in the G6PD gene
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Approval from the institutional Ethics Committee
of  Cukurova  University  Medical  Faculty  was
provided and informed consent was obtained from
all subjects prior to enrolment in the study.
Results 
A screening protocol was performed and of 450
subjects, 32 were found to have G6PD deficiency.
Genomic  DNA  samples  from  these  32  G6PD-
deficient individuals were analyzed, and 15 subjects
were found to be hemizygous, five cases were
homozygous, one case was heterozygous, whereas
eleven subjects were shown to be the wild-type
(Figure 1). That is, the percentage of the G6PD-
deficient individuals with 1311 polymorphism was
4.7% in our study group. G6PD activity, fluorescence
signal rate and molecular features of the cases are
detailed in Table I and Table II. 
Discussion
The presence of a mutation, a silent C-to-T
change, at nucleotide 1311 in exon 11 of the G6PD
gene was first noticed when DNA samples from
subjects  with  G6PD  Mediterranean  (Gd-Med)
mutation were sequenced by De Vita et al. [19].
Since then, 1311 polymorphism has been shown to
be quite prevalent among G6PD-deficient people,
particularly in those with Gd-Med mutation, and
has been reported in many countries all over the
world including Portugal, Pakistan, Sardinia, and
Tunisia [20-23].
1311 mutation has been considered as a poly  -
morphic marker of the G6PD gene, independent of
G6PD  deficiency.  Nevertheless,  studying  the 
1311 polymorphism in subjects with G6PD Mediter  -
ranean mutation could help us to recognize the
spread  of  this  mutation  [24].  Using  sequence
analysis, Beutler and Kuhl studied the distribution
of the nucleotide polymorphism C1311T in cases
with  and  without  G6PD  deficiency  in  diverse
populations in 1990. They found that out of 21 Gd-
Med individuals from Mediterranean countries, 20
had a T at nucleotide 1311, whereas neither of two
Gd-Med cases from the Indian subcontinent had
1311 polymorphism. The investigator concluded that
the Gd-Med mutation may have arisen indepen  -
dently in Europe and in Asia, since the vast majority
of  European  subjects  with  Gd-Med  had  1311
polymorphism [14].
Moiz et al. reported that the 1311 polymorphism
was seen frequently both in subjects with Gd-Med
mutation and in healthy individuals in Pakistan [21].
Similarly, Sukumar et al. reported a high frequency
of 1311 polymorphism in Gd-Med and G6PD Kerala-
Kalyan Indians [24]. Using the PCR-RFLP technique,
Nuchprayoon et al. identified the G6PD mutations
in two different ethnic groups in Thailand, and
reported that the 1311 polymorphism was common
both in G6PD-deficient and in normal cases [25].
According to the data of Ruzzo et al. from Italy, in
the normal population of southern Italy, which is at
risk for Gd-Med mutation, the 1311 polymorphism
was 16.7-20%, whereas in the Marche region, in
central Italy, the 1311T frequency was found to be
about one half of that found in southern Italy [26].
In Great Britain, the incidence of this silent mutation
C Ca as se e   n no o. .    G G6 6P PD D   a ac ct ti iv vi it ty y    G Gd d- -M Me ed d    G Ge en no ot ty yp pe e   1 13 31 11 1
a an nd d   s se ex x [ [U U/ /g gH Hb b] ] m mu ut ta at ti io on n
1. Control  –– Control
2. M 0.0 Hemizygous Hemizygous
3. F 3.7 Heterozygous Normal
4. M 0.0 Hemizygous Hemizygous
5. F 2.3 Heterozygous Normal
6. F 4.6 Hemizygous  Normal
7. M 0.0 Hemizygous Hemizygous
8. M 0.0 Hemizygous Normal
9. M 0.0 Hemizygous Normal
10. M 0.0 Hemizygous Normal
11. F 0.0 Homozygous  Normal
12. F 4.1 Heterozygous Heterozygous
13. F 1.5 Heterozygous Homozygous
14. F 3.6 Heterozygous Homozygous
15. F 2.8 Heterozygous Normal
16. M 0.0 Hemizygous Hemizygous
17. M 0.0 Hemizygous Hemizygous
18. M 0.0 Hemizygous Hemizygous
19. F 3.9 Heterozygous Homozygous
20. M 0.0 Hemizygous Hemizygous
21. F 4.9 Heterozygous Homozygous
22. M 0.0 Hemizygous Hemizygous
23. M 0.0 Hemizygous Hemizygous
24. M 0.0 Hemizygous  Normal
25. M 0.0 Hemizygous Hemizygous
26. M 0.0 Hemizygous Hemizygous
27. F 2.3 Heterozygous  Homozygous
28. M 0.0 Hemizygous Hemizygous
29. M 0.0 Hemizygous Hemizygous
30. M 0.0 Hemizygous Hemizygous
31. M 0.0 Hemizygous Hemizygous
32. F 4.2 Heterozygous  Normal
33. M 0.0 Hemizygous Normal
T Ta ab bl le e   I II I. .   G6PD activity, the type of Gd-Med mutation
and the genotype of 1311 polymorphisms in the
study group 
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among British was reported to be 24%, while
among Iranian subjects it was 44%. It seems that
the incidence of the silent mutation is higher in the
population of the Mediterranean basin than among
populations of continental Europe [27].
Similar studies were performed by Kurdi-Haidar
et al. in 20 unrelated individuals with Gd-Med
mutation from Saudi Arabia, Iraq, Iran, Jordan,
Lebanon, and Israel. Except for one subject, all of
the cases were shown to have the C-to-T change at
nucleotide 1311. Kurdi-Haidar et al. concluded that
the  silent  mutation  is  an  independent  poly  -
morphism in the Middle East, and that the mutation
leading to Gd-Med deficiency probably arose on
a chromosome  that  already  carried  the  silent
mutation [11].
Inconsistent with the above-mentioned reports,
the rate of 1311 polymorphism among our study
group was found to be low, with a percentage of
4.7%. The most reasonable explanation for this may
be the extremely diverse ethnic background of the
Adana population, which may be due in part to the
high level of immigration into this region. The G6PD
deficiency is mainly found in malaria-endemic areas,
and accordingly, it was hypothesized that G6PD
deficiency had arisen as a protective factor against
lethal malaria [28]. Consistent with this data, the
number of G6PD-deficient cases was reported to
be significantly elevated in Adana, which has been
reported as one of the malaria-endemic regions in
Turkey [8]. By using the microarray technique,
Menziletoglu Yildiz et al. revealed in a recent study
that the frequency of the Gd-Med mutation was
found to be substantially high in subjects with
G6PD deficiency in Adana [29]. However, the reason
why  the  number  of  subjects  with  1311  poly  -
morphism was observed to be significantly lower
than expected and also below that reported by the
other Mediterranean countries may be the very
heterogeneous population residing in this area. It
is also most likely that many variants of G6PD
deficiency may exist in this area due to this highly
divergent ethnicity.
The PCR-based assays have been widely utilized
to  detect  the  G6PD  mutations  and  1311  poly  -
morphism. To our knowledge, this study repre  sents
the  first  report  of  1311  polymorphism  in  the
Cukurova Region with the microarray technique.
The Nanogen® microarray system enabled us to
design  a new  probe  to  detect  the  1311  poly  -
morphism in G6PD-deficient cases, and the results
obtained from the newly designed microarray probe
were confirmed by the RFLP. We suggest that the
microarray technique can be safely utilized not only
for analysis of mutations and gene expression, but
also  for  detecting  the  single  nucleotide  poly  -
morphisms. Furthermore, it seems that it can also
be used to develop new applications as it can be
easily modified. After the appropriate infrastructure
has been established, the cost of the chemical
substance required for the procedure may greatly
decrease,  particularly  when  large  numbers  of
samples need to be processed in a short period of
time and with a minimum of handling.
In conclusion, studying the polymorphisms of
the G6PD gene may facilitate the identification of
the genetic basis of G6PD deficiency in different
regions and in various ethnic groups. Furthermore,
DNA polymorphisms have been shown to be very
supportive in the study of the human genome by
providing markers for gene mapping as well as
linkage analysis [30]. Although the G6PD gene holds
a substantial number of polymorphic sites, whether
these genetic variants including the nucleotide
C1311T polymorphism could help us to understand
the differences in disease severity in G6PD-deficient
individuals from distinct populations needs to be
further clarified by additional investigations. 
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